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Abstract: Overexpression of the efflux pump P-glycoprotein (P-gp) is one of the important 
mechanisms of multidrug resistance (MDR) in many tumor cells. In this study, 26 novel 5-oxo-
hexahydroquinoline derivatives containing different nitrophenyl moieties at C
4
 and various 
carboxamide substituents at C
3
 were designed, synthesized and evaluated for their ability to 
inhibit P-gp by measuring the amount of rhodamine 123 (Rh123) accumulation in uterine sarcoma 
cells that overexpress P-gp (MES-SA/Dx5) using flow cytometry. The effect of compounds 
with highest MDR reversal activities was further evaluated by measuring the alterations of 
MES-SA/Dx5 cells’ sensitivity to doxorubicin (DXR) using MTT assay. The results of both 
biological assays indicated that compounds bearing 2-nitrophenyl at C
4
 position and compounds 
with 4-chlorophenyl carboxamide at C
3
 demonstrated the highest activities in resistant cells, 
while they were devoid of any effect in parental nonresistant MES-SA cells. One of the active 
derivatives, 5c, significantly increased intracellular Rh123 at 100 µM, and it also significantly 
reduced the IC
50
 of DXR by 70.1% and 88.7% at 10 and 25 µM, respectively, in MES-SA/Dx5 
cells. The toxicity of synthesized compounds against HEK293 as a noncancer cell line was also 
investigated. All tested derivatives except for 2c compound showed no cytotoxicity. A molecular 
dynamics simulation study was also performed to investigate the possible binding site of 5c in 
complex with human P-gp, which showed that this compound formed 11 average H-bonds with 
Ser909, Thr911, Arg547, Arg543 and Ser474 residues of P-gp. A good agreement was found 
between the results of the computational and experimental studies. The findings of this study 
show that some 5-oxo-hexahydroquinoline derivatives could serve as promising candidates for 
the discovery of new agents for P-gp-mediated MDR reversal.
Keywords: cancer, P-glycoprotein, multidrug resistance, 1,4-dihydropyridine, molecular 
dynamics simulation
Introduction
Despite recent progress in the elucidation of cancer biology and development of novel 
strategies in cancer diagnosis and treatment, this disease is still among the leading 
causes of death around the world.1 The resistance of malignant cells to structurally 
and mechanistically unrelated classes of anticancer agents is recognized as MDR.2 
Different mechanisms are involved in drug resistance; a very important one is overex-
pression of P-gp (ABCB1, MDR1), which has been one of the first members of ABC 
transporters to be studied.3 P-gp extrudes a wide variety of endogenous molecules 
and xenobiotics and plays an important physiological role in detoxifying cells from 
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exogenous toxic agents.4 However, overexpression of P-gp 
in cancer cells leads to reduced accumulation of chemothera-
peutic drugs and results in resistance against these agents.5 In 
this context, inhibition of P-gp by small-molecule inhibitors 
seems to be a promising approach for overcoming MDR in 
cancer cells.6
Three different generations of P-gp inhibitors have been 
discovered. The first-generation inhibitors such as verapamil, 
cyclosporine A and quinidine7 were developed for other 
applications and then tested for P-gp inhibition. The second- 
(such as valspodar8) and third-generation inhibitors (such as 
elacridar,9 tariquidar,10 laniquidar11 and zosuquidar12) were 
specifically designed for MDR reversal and did not display 
other pharmacological effects. However, clinical results of 
these agents were unsatisfactory due to insufficient therapeu-
tic benefit and unacceptable systemic toxicity.
Initial studies on calcium channel blockers demonstrated 
that verapamil and diltiazem were able to reverse MDR by 
increasing intracellular levels of chemotherapeutic agents.13 
Afterward, Safa et al confirmed P-gp-inhibitory effect of 
calcium channel blocker azidopine belonging to the family 
of 1,4-DHP derivatives.14 Other authors have also reported 
the MDR reversal effect of a set of synthesized DHPs.15
SAR studies of DHPs show that replacement of car-
boxylate esters at C
3
 and C
5
 positions with aryl carboxamide 
groups dramatically diminishes their cardiovascular effects. 
We have previously studied the synthesis and biological eval-
uation of symmetric and asymmetric 1,4-DHPs containing 
different carboxamide substitutions at mentioned positions 
and observed that these compounds had poor calcium-
channel-blocking activity compared to nifedipine.16–19
The compounds bearing DHP core have been shown to 
display a broad range of biological and pharmacological 
effects.16 Besides their calcium-channel-blocking activity,20–22 
they have shown therapeutic effects against Alzheimer’s 
disease and atherosclerosis23 and have also shown MDR 
reversal effect.20,24,25
Three decades after the discovery of P-gp, lots of efforts 
have been made on the development of novel P-gp inhibi-
tors, but no small-molecule inhibitor has been identified for 
clinical use. In an attempt to respond to this crucial need for 
novel therapeutic agents and as part of our research program 
toward the discovery of useful MDR reversal agents, herein 
we report synthesis, biological evaluation and MD simula-
tions study of a set of 26 novel 5-oxo-hexahydroquinoline 
derivatives. The experimental results showed that these 
compounds can indeed inhibit P-gp, and these findings were 
in good agreement with the computational findings.
Results and discussion
Fragment-based design
Several efforts have been made to clarify the basic features 
that are responsible for the MDR reversal effect of DHPs. 
In our previous studies, we described the design, synthe-
sis and in vitro data of a series of new inhibitors of P-gp 
with 1,4-DHP structure carrying 2- or 3-pyridyl methyl 
carboxylate at C
3
 with different alkyl carboxylate moieties 
at C
5
 position as well as nitrophenyl or heteroaromatic rings 
at C
4
 of central DHP core.26,27 Herein, we report a fragment-
based design for a new set of 5-oxo-hexahydroquinoline 
derivatives based on a previously established SAR for 
reported DHPs (Scheme 1).
– The 5-oxo-hexahydroquinoline scaffold was chosen 
based on the observation that DHP pharmacophore 
exhibits MDR reversal effect.15
– The presence of nitroaryl substituents at C
4
 position 
has previously proved to enhance MDR reversal effect 
compared to heteroaryl rings.
– Substitution of different moieties bearing nitrogen at C
3
 
such as carboxamide group resulted in increasing MDR 
reversal effect of designed compounds. Accordingly, 
different pyridyl methyl carboxylates at C
3
 position26,27 
were bioisosterically replaced with alkyl or aryl 
carboxamides.
Many studies have revealed that natural products with 
fused rings such as quercetin are MDR reversal agents.28 
Based on these findings, bioisosteric replacement and 
hybridization of 4H-chromen-4-one ring of quercetin 
with 4,6,7,8-tetrahydroquinolin-5(1H)-one in DHP-based 
designed compounds would be expected to improve MDR 
reversal activity.29,30
Thus, in this study, a library of 26 compounds with 5-oxo-
hexahydroquinolone skeleton bearing different nitrophenyl 
moieties at C
4
 and different aryl or alkyl carboxamides at 
C
3
 was designed.
chemistry
The applied route for synthesis of designed compounds is 
outlined in Scheme 2, and the structures are presented in 
Table 1. By the reaction of the commercially available differ-
ent primary and secondary amines (1) with 2,2,6-trimethyl-
4H-1,3-dioxin-4-one (2), corresponding 3-oxobutanamides 
(1a–6a) were obtained (Table 2). The final products were 
synthesized by the reaction of obtained intermediates (1a–6a) 
with different aryl aldehydes and 1,3-cyclohexadione in the 
presence of excess amounts of ammonium acetate (Table 1). 
All compounds were completely purified and characterized 
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using 1H NMR, 13C NMR and mass and IR spectroscopy 
(Supplementary materials).
Biological evaluation
rh123 accumulation assay
The P-gp-mediated Rh123 efflux was determined by flow 
cytometry on the DXR-resistant uterine sarcoma MES-SA/
Dx5 cell line and its parental nonresistant MES-SA cell line.31 
Verapamil was used as a positive control. MES-SA/Dx5 is 
a resistant cell line, which overexpresses P-gp as a result of 
continuous exposure to DXR. Alterations in the amount of 
the fluorescent Rh123 retained inside the MES-SA-Dx5 cells 
can be logically related to the inhibition of the activity of 
P-gp efflux pump in the cells. Figure 1 shows a representative 
histogram of the effect of different doses of compound 2f 
on the intracellular accumulation of Rh123 in resistant cells. 
A dose-dependent response can be clearly observed at 5, 25 
and 100 µM on Rh123 accumulation as the histogram shifts 
to the right. All the active compounds except 2c showed a 
dose-dependent effect. The results are expressed as Rh123 
Scheme 1 Fragment-based design of P-gp inhibitors using DhP backbone.
Abbreviations: P-gp, P-glycoprotein; DhP, dihydropyridine; MDr, multidrug resistance.
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Table 1 chemical structures of synthesized 5-oxo-hexahyroquinoline derivatives
1+
2$U2
15
5
Compounds Ar R1 R2 Compounds Ar R1 R2
1c 12 h 7d 12 ch3– ch2----- ch3– ch2-----
2c 12 &O h 8d 12 ch3----- ch3-----
3c 12 21 h 1e 12 h
4c 12 +22& h 2e 12 &O h
5c 12 2
h 3e 12 21 h
6c 12 1& h 4e 12 +22& h
7c 12 ch3– ch2----- ch3– ch2----- 5e 12 2
h
1d 12 h 6e 12 1& h
2d 12 &O h 7e 12 ch3– ch2----- ch3– ch2-----
3d 12 21 h 1f h
4d 12 +22& h 2f &O h
5d 12
2
h 3f ch3– ch2----- ch3– ch2-----
6d 12 1& h 4f ch3----- ch3-----
Drug Design, Development and Therapy 2017:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
411
a study of 5-oxo-hexahydroquinoline derivatives
DHP ring showed the highest levels of Rh123 accumulation 
and P-gp inhibition at 100 µM. Compounds 2c and 5c also 
exhibited a considerable MDR reversal activity at 25 and 
100 µM, respectively.
Considering the data presented in Figure 2, a brief SAR 
can be deduced as shown in Figure 3.
In different series of synthesized compounds, those 
bearing 2-nitrophenyl substitution at C
4
 such as 1c, 2c, 3c, 
5c and 6c were the most potent derivatives. This reveals that 
the presence of 2-nitrophenyl moiety is crucial in enhancing 
the potency.
– Compounds containing N-(4-chlorophenyl) carboxamide 
at C
3
 (2c, 2d and 2f) exhibited good MDR reversal effect. 
For example, compound 2f showed 6.0-fold Rh123 accu-
mulation relative to the negative control.
– None of the compounds bearing 4-carboxyphenyl moi-
ety at C
3
 (4c, 4d and 4e) were effective MDR reversal 
agents. 4c and 4d exhibited only 1.32-fold Rh123 
accumulation.
As shown in Figure 4, the effects of synthesized com-
pounds were specific against resistant MES-SA/Dx5 cell 
line, because Rh123 accumulation was not observed in the 
parental MES-SA cells.
Determination of chemosensitization in resistant 
cells induced by synthesized compounds
Effects of synthesized compounds on the alteration of 
MES-SA/Dx5’s sensitivity to DXR were evaluated by MTT 
assay, in which cell viability is measured spectrophotometri-
cally by the amount of reduced formazan. For this purpose, 
the most potent compounds were selected based on the results 
of Rh123 accumulation assay. To select a nontoxic concentra-
tion (cell survival .85%), cytotoxicity assay was performed 
on P-gp-expressing MES-SA/Dx5 cell line. On the basis 
of the obtained results, maximum concentration was set to 
25 µM (data not shown). The effects of coadministration of 
synthesized compounds and DXR were then studied in these 
cells. The percent reduction of DXR’s IC
50
 was calculated 
(Figure 5). DXR showed a relative low activity in the assay 
of cell survival (IC
50
: 2.7 µM). The compounds 1c and 3c 
at 25 µM decreased the DXR’s IC
50
 by 47.7% and 69.8%, 
respectively, and did not show any considerable chemosensi-
tization effect. Compound 2f, which was the most potent com-
pound in the Rh123 accumulation assay, showed a moderate 
activity in this assay. The most potent compound 2c bearing 
2-nitrophenyl at C
4
 and 4-chlorophenycarboxamide at C
3
 
showed 92.3% and 99.2% decrease in the IC
50
 of DXR at 10 
and 25 µM, respectively. The other 2-nitrophenyl-containing 
compound 5c with 4-methoxyphenyl substitute at C
3
 also 
Table 2 chemical structure of synthesized intermediates (1a–6a)
Compounds Product MW (g/mol) Yield (%)
1a +1 2 2
177.20 82
2a +1 2 2&O
211.65 91
3a
2
+1
221
222.20 75
4a
2
1+
2 2+
2 221.21 56
5a 2
1+
2 1 202.21 78
6a 2
1+
2 2 207.23 85
Figure 1 Flow cytometric histogram of 2f demonstrating Rh123 fluorescence in 
Mes-sa/Dx5 cell line. cells were pretreated with 5, 25 and 100 µM of synthesized 
compounds for 20 min and then exposed to 5 µM rh123 for another 20 min at 37°c. 
The cells were then washed three times with ice-cold PBs. Fluorescence intensity 
caused by intracellular Rh123 accumulation was measured by an FACSCalibur flow 
cytometer at 488 and 530 nm excitation and emission wavelengths, respectively.
Abbreviations: rh123, rhodamine 123; PBs, phosphate-buffered saline.
256
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Rh 123
accumulation fold increase, representing the ratio of Rh123 
fluorescence in the presence and absence of synthesized com-
pounds (Figure 2). Compound 2f bearing phenyl substitute at 
C
4
 and N-(4-chlorophenyl) carboxamide at C
3
 position of the 
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Figure 2 The effect of synthesized compounds on the intracellular accumulation of rh123 in Mes-sa/Dx5 cell line. cells were pretreated with 5, 25 or 100 µM of synthesized 
compounds for 20 min and then exposed to 5 µM rh123 for another 20 min at 37°c. The cells were then washed three times with ice-cold PBs. rh123 retained in cells 
was measured by flow cytometry at 488 and 530 nm excitation and emission wavelengths, respectively. Rh123 accumulation fold increases were calculated by dividing 
the mean fluorescence intensity obtained for each compound by that of control cells. The effects of synthesized compounds with 2-nitrophenyl (A), 3-nitrophenyl (B), 
4-nitrophenyl (C) and phenyl (D) at c4 position and verapamil as positive control are shown. Data are presented as mean ± seM of three to four independent measurements. 
*The difference between Rh123 accumulation folds in the absence and presence of test compound is significant (P,0.05).
Abbreviations: rh123, rhodamine 123; PBs, phosphate-buffered saline; seM, standard error of the mean.
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Figure 3 structure–activity relationship study and the effect of substituted moieties 
on MDr reversal activity of target compounds obtained from rh123 accumulation 
assay against Mes-sa/Dx5 cells. Upside and downside arrows demonstrate that the 
substitutions had a positive or a negative influence on the MDR reversal potential, 
respectively.
Abbreviations: MDr, multidrug resistance; rh123, rhodamine 123.
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observed between the results of Rh123 accumulation assay 
and DXR uptake in resistant cells.
cytotoxicity against heK293 cells
In order to determine the effect of synthesized compounds 
on HEK293 (human embryonic kidney) cells used as a nor-
mal cell line, the MTT assay was performed. The cells were 
treated with the test compounds at concentrations of 5, 10 
and 25 µM for 48 h. The obtained results (Figure 6) revealed 
that all compounds exhibited no cytotoxicity against normal 
cells (viability .80%) except compound 2c which showed 
54.9% viability at 25 µM.
computational approach
Different studies have been focused on the elucidation of 
the mechanism of action of synthesized DHPs on P-gp and 
identification of possible binding sites of DHPs. To this 
purpose, domain mapping using photoaffinity labeling along 
with immunoprecipitation of different DHP derivatives has 
confirmed that the binding site is located near the N-terminal 
resulted in 70.1% and 88.7% decrease in the IC
50
 of DXR 
at 10 and 25 µM, respectively. The other tested compounds 
were able to induce a statistically significant decrease in the 
IC
50
 of DXR at 10 and 25 µM, and a good correlation was 
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Figure 4 The effect of synthesized compounds on the intracellular accumulation of rh123 in Mes-sa cell line. cells were pretreated with 5, 25 and 100 µM of synthesized 
compounds or 5 and 25 µM of verapamil for 20 min and then exposed to 5 µM of rh123 for another 20 min at 37°c. The cells were then washed three times with ice-
cold PBS. Mean fluorescence intensity caused by Rh123 was evaluated by flow cytometry at 488 and 530 nm excitation and emission wavelengths, respectively. The Rh123 
accumulation fold increases were calculated by dividing the mean fluorescence intensity obtained for each compound by that of control cells. The effects of synthesized 
compounds with 2-nitrophenyl (A), 3-nitrophenyl (B), 4-nitrophenyl (C) and phenyl (D) at c4 position and verapamil as positive control are shown. Data represent mean ± 
SEM of three independent measurements. No significant difference was observed between Rh123 accumulation in the absence and presence of synthesized compounds for 
any of the derivatives (P.0.05).
Abbreviations: rh123, rhodamine 123; PBs, phosphate-buffered saline; seM, standard error of the mean.
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Figure 5 The effect of synthesized compounds on the reduction of doxorubicin’s 
cytotoxicity in Mes-sa/Dx5 cell line. cells were seeded in 96-well microplates and 
cultured overnight. They were then treated with 5, 10 and 25 µM of test compounds. 
after 90 min, doxorubicin was added. The cells were further incubated for 48 h, 
and then the MTT assay was performed. in the absence and presence of synthesized 
compounds, ic50 values and percent reduction of doxorubicin’s ic50 values were 
calculated. Mean values (±seM) are the average of three independent experiments each 
done in triplicate. *The difference between the percent reduction of doxorubicin’s 
ic50 values in the absence and presence of test compounds is significant (P,0.05).
Abbreviation: seM, standard error of the mean.
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nucleotide-binding domain of P-gp.32 Ferry et al proposed that 
DHP-binding site that is located in the cytoplasmic region of 
P-gp comprises residues 491–525.33 Other investigators have 
used a dexniguldipine-HCl ([3H] B9209-005) to probe the 
DHPs’ binding site showing that residues 468–527 are the 
ligand-interacting region of the protein. These findings show 
that DHP derivatives probably bind to the nucleotide-binding 
domain of P-gp, inhibiting the action of this efflux pump.34
In order to explore the structural requirements of 5-oxo-
hexahydroquinoline derivatives which determine their inter-
action with P-gp, we chose the most favorite pose of one of 
the most potent and nontoxic compounds 5c from docking 
study and placed it in the proposed active site of homology-
modeled P-gp. The crystal structure of murine P-gp (PDB 
ID: 3G5U, chain A, resolution: 3.8 Å) served as a template 
to create homology models of human P-gp (UNIPORT ID: 
P08183). The alignment of human P-gp and mouse P-gp 
sequences shows 87% identity. The QMEAN Z-score of 
the obtained models ranged from -2.35 (best) to -4.14. 
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All models obtained from GA341 showed the highest 
possible value of 1. The derived backbone conformation was 
inspected by Ramachandran plot which showed that 83.8% 
of the residues lie in most favored, 12.1% in additionally 
allowed, 3.3% in generously allowed and 0.8% in outlier 
regions. These results indicate that the phi and psi backbone 
dihedral angles in the obtained model are precise.
We incorporated our results into the model for the P-gp 
ligand–receptor interaction that is shown in Figure 7. This 
configuration is the midpoint structure of most populated 
cluster obtained by clustering analysis of MD trajectories 
(data not shown). Clustering was performed using Cα 
backbone atoms, least squares alignment and the Gromos 
algorithm35 (cutoff: 0.15 nm) by g_cluster module as 
implemented in Gromacs 4.6.5. As shown in Figure 7B, 
cyclohexanone moiety of the ligand participates in hydro-
phobic interactions with the side chains of Arg905, Phe904 
and Val472.36 There is another hydrophobic interaction that 
occurs between N-(4-methoxyphenyl) part of ligand and 
side chain of Val478 as well as phenyl moiety of Tyr490. 
In order to investigate hydrogen-bonding profile of ligand 
and receptor, we used g_h bond module implemented in 
Gromacs 4.6.5 with H-bond forming a distance of 3.5 Å 
and an angle of 120°. Table 3 includes all information 
about hydrogen-bonding pattern obtained during 10 ns 
MD simulation. The analysis revealed that compound 5c 
forms eleven average H-bonds sharing nine H-bonds with 
Ser909, Thr911, Arg547, Arg543 and Ser474 as accep-
tors. Oxygen atom of N-(4-methoxyphenyl) carboxamide 
pendant at C
3
 formed the most stable H-bond with Arg543 
with occupancy of 81% (some interactions are not shown 
for clarity). This is in good agreement with our SAR 
studies which proves that the N-(4-methoxyphenyl) moiety 
increases the MDR reversal effect of this ligand. Further 
analysis of ligand interaction with active site residues 
revealed a π–cation interaction between nitrogen atom 
of Arg543 and 2-nitrophenyl ring. In summary, we here 
propose 3D models of complexes of P-gp with a promising 
5-oxo-hexahydroquinoline reversal agent that is consistent 
with our SAR studies.
Figure 7 interaction of compound 5c with P-gp protein. P-gp binding pocket (A) and the direct contact of 5c with the active site of P-gp are depicted (B). ligand is shown as 
orange sticks and the side chains as cyan. hydrogen bonds, hydrophobic interactions and π–cation interaction are shown as dashed blue, gray and orange lines, respectively. 
solvent and lipids are not shown for clarity.
Abbreviation: P-gp, P-glycoprotein.
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Figure 6 The effect of synthesized compounds on heK293 cells. heK293 cells 
were seeded in 96-well culture plates and cultured overnight. They were then 
treated with the synthesized compounds at 5, 10 and 25 µM. The cells were further 
incubated for 48 h, and then MTT assay was performed. *The difference between 
the test compound and control untreated cells is significant (P,0.05).
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Experimental section
chemistry
All melting points were taken on a hot stage apparatus 
(Electrothermal, Essex, UK) and were reported uncorrected. 
IR spectra were recorded with a Perkin-Elmer spectrometer 
(KBr disk) (PerkinElmer, Waltham, MA, USA). NMR 
spectra were recorded on a Bruker Avance 300 spectrometer 
(300 MHz for 1H NMR, 75 MHz for 13C NMR). Mass 
spectra were obtained with an Agilent spectrometer (9575c 
inert MSD; Agilent Technologies, Santa Clara, CA, USA). 
Chromatographic separations were performed on a silica 
gel column by gravity chromatography (Kieselgel 40, 
0.063–0.200 mm; Merck) or flash chromatography (Kieselgel 
40, 0.040–0.063 mm; Merck). Yields are given after purifi-
cation, unless otherwise stated. All compounds were named 
following IUPAC guidelines as defined by ChemBioDraw 
Ultra 12.0 software.
3-Oxo-n-substituted phenylbutanamide
Ten milliliters of xylene was added to a mixture of 2,2,6-
trimethyl-4H-1,3-dioxin-4-one (6 mmol) and different 
primary or secondary amines (5 mmol). The reaction mixture 
was refluxed for 2–4 h. After completion of the reaction as 
monitored by thin-layer chromatography, the mixture was 
cooled and transferred to a separating funnel and washed with 
petroleum ether (30–50 mL). The solid product was collected 
and dried (Table 2). Compounds 3a and 4a were reported 
previously.37 N,N-Diethyl acetoacetamide and N,N-dimethyl 
acetoacetamide were commercially available. The NMR data 
are reported in the Supplementary materials.
reagents
All reagents were purchased from Sigma-Aldrich (St Louis, 
MO, USA) if not specifically stated, and were ultrapure grade. 
Penicillin/streptomycin was purchased from Invitrogen. 
FBS, PBS, RPMI 1640 and trypsin were purchased from 
Biosera. DXR was obtained from EBEWE Pharma. Rh123 
was purchased from Sigma-Aldrich.
cell culture and treatment
Human uterine sarcoma cell line MES-SA and its multidrug-
resistant counterpart MES-SA/Dx538 obtained by continuous 
in vitro exposure to DXR were used in this study. Both 
cell lines were obtained from Sigma-Aldrich. Cells were 
grown in RPMI 1640 medium supplemented with 10% 
heat-inactivated FBS and 1% penicillin/streptomycin at 
37°C and in incubators having humidified air containing 5% 
CO
2
. Resistant cells were cultured in the presence of 100 nM 
DXR, which was removed from the media 24 h before each 
experiment. HEK293 cell line (obtained from Pasteur Insti-
tute of Iran) was also used in this study. This cell line was 
maintained in Dulbecco’s Modified Eagle’s Medium F12 
supplemented with 10% FBS, 1% l-glutamine and 1 mL 
penicillin/streptomycin.
A 0.05% trypsin solution was used to detach the cells 
from culture flasks. Test compounds and verapamil were 
prepared in DMSO at 40 mM stock solutions, and DXR 
was prepared in complete medium at 10 mM. Drugs and test 
compounds were then diluted with complete culture medium 
to obtain the final test concentrations. Maximum concentra-
tion of DMSO in wells did not exceed 0.25%.
Flow cytometric determination of rh123 
accumulation
Accumulation of intracellular Rh123, a P-gp substrate, 
inside resistant and nonresistant cells was measured by flow 
cytometry as an index of P-gp inhibition. A suspension of 
MES-SA/Dx5 or MES-SA cells was prepared at a density 
Table 3 analysis of hydrogen bond formation between inhibitor 
and P-gp
1
2
1
22
1
2±
2
+



 



+
Donor residue 
(atom)
Acceptor residue* 
(atom)
Distance 
D–A (Å)**
Occupancy*** 
(%)
5c (h11) glu476 2.25 55.1
5c (h11) glu476 2.29 56.1
ser909 5c (O26) 3.71 32.1
ser909 5c (n9) 3.60 26.5
ser909 5c (O23) 3.01 10.9
ser909 5c (n21) 3.51 11.3
Thr911 5c (O26) 2.99 10.8
arg547 5c (O22) 5.17 17.0
arg543 5c (O24) 1.83 80.9
arg543 5c (O24) 3.45 12.9
ser474 5c (n12) 2.95 18.2
Notes: *atom names are based on amber nomenclature. **Distance between 
donor and acceptor atoms. ***Percentage of time the hydrogen bond is intact.
Abbreviations: P-gp, P-glycoprotein; D–a, Donor–acceptor distance.
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of 5×105 cells/mL in serum-free RPMI 1640. Half of the 
cell suspensions was placed in 1.5 mL tubes. Different 
concentrations of target compounds taken from prepared 
stock solutions in DMSO were added in a volume of 0.4 mL. 
After 20 min of incubation at 37°C, the P-gp substrate Rh123, 
was added in a volume of 100 µL at a final concentration 
of 5 µM. Incubation was continued for another 20 min at 
37°C. Later, the cells were centrifuged and washed three 
times with ice-cold PBS and were resuspended in PBS for 
measurements. The control cells were treated in the same 
way without being treated with any inhibitor. A total of 
2×104 cells were counted. The fluorescence uptake of Rh123 
within a number of cells was determined by an FACSCalibur 
flow cytometer (Becton Dickinson, Franklin Lakes, NJ, 
USA). The results are expressed as Rh123 accumulation 
fold increase, which was defined as geometric mean value of 
Rh123 fluorescence in the cells treated with the synthesized 
compounds or verapamil relative to the geometric mean value 
of the control cells.
Determination of alteration of resistant 
cells’ sensitivity to DXr by MTT assay
The assessment of DXR’s cytotoxicity was performed on 
exponentially growing resistant MES-SA/Dx5 cells. Cells 
were seeded in 96-well plates at a density of 5×104 cells/mL 
in a final volume of 100 µL for 24 h. They were then treated 
with 1, 3 or 10 µM DXR in the presence or absence of 
synthesized compounds at different concentrations (5, 10 
or 25 µM) for 90 min. After incubation for 48 h at 37°C, 
supernatants were carefully discarded, and 80 µL of MTT 
reagent (0.5 mg/mL) was added to each well, allowing viable 
cells to reduce the MTT solution to formazan crystals. After 
4 h, the supernatants were discarded, and 200 µL DMSO was 
added to dissolve the formazan crystals. The absorbance of 
the solution was then read by a microplate reader at a wave-
length of 570 nm with background correction at 675 nm. The 
final results are expressed as percent reduction of DXR’s IC
50
, 
which is calculated based on DXR’s IC
50
 in the absence and 
presence of synthesized compounds.
assessment of cytotoxicity against 
heK293 cells
HEK293 cells were seeded in 96-well culture plates at a 
density of 2,000 cells/well and allowed to attach. After 24 h 
incubation at 37°C in 5% CO
2
, the culture medium was 
removed and replaced with fresh medium containing the 
target compounds at different concentrations and further 
incubated at 37 CC for 48 h. Afterward, 80 µL of MTT 
solution (0.5 mg/mL) was added to all wells and incubated 
for 4 h. The medium was then removed, and 200 µL DMSO 
was added into each well to dissolve formazan crystals. After 
another hour of incubation, the mixture was gently shaken 
for 30 min. The absorbance was measured using a microplate 
reader at the wavelength of 570 nm. Each concentration 
was tested in duplicate, and the experiments were repeated 
three times.
MD simulation study of 5c in complex 
with human P-gp
In order to better understand the mode of interaction of 
synthesized compounds with P-gp receptor, MD simula-
tion was applied to the complex of ligand and receptor. 
We precisely constructed the homology model of P-gp 
based on the murine P-gp (PDB entry: 3G5U)39 using 
Clustal Omega program from its website http://www.ebi.
ac.uk/Tools/msa/clustalo/. One thousand 3D models of 
P-gp were generated, using MODELLER 9v2 program,40 
and they were evaluated using GA341 method. The 
models with lowest DOPE score values were selected for 
further computational studies. The loops were remodeled 
using the quantum mechanical method in the MOD-
ELLER software. QMEAN Z-score from the website 
http://swissmodel.expasy.org/qmean/cgi/index.cgi41 was 
employed for checking the stereochemical quality of the 
selected models.
Afterward, the model was inserted in the POPC phospho-
lipids bilayer and subjected to 80 ns MD simulation to inves-
tigate the stability as well as structural and conformational 
changes during simulation. In this work, one of the most 
potent inhibitors among all the synthesized ligands was cho-
sen and placed in the active site of the P-gp. Ligand–receptor 
complex was then inserted in POPC lipid bilayer, and 20 ns 
MD simulation was performed. Initial configuration of the 
ligand was acquired via docking procedure. At first, ligand 
was sketched using MarvinSketch, and then the structure 
was optimized by density functional theory, B3LYP/3-21 
level using ORCA software. Optimized structure of the 
ligand was then docked to P-gp model, which was obtained 
previously. The molecular docking was conducted using 
AutoDock Vina.42,43 The grid box was set at 18×18×18 with 
a spacing value of 1 Å. The best conformation with the least 
binding energy and better interacting residues was selected. 
Full general amber force field44 topology/coordinate files 
were created using the programs Parmchk and Tleap of the 
AmberTools package45 to describe van der Waals and bonded 
parameters for the ligand. Partial atomic charges were then 
assigned based on the RESP ESP charge Derive Server.46 
The AMBER format files of the ligands were converted to 
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the Gromacs format using the ACPYPE python tool.47 The 
most favorite pose from the docking study was selected as 
the starting structure for MD simulation.
statistical analysis
The data, expressed as the mean ± SEM, were analyzed by 
one-way ANOVA using the SPSS software version 14.0 
for Windows. Differences with P,0.05 were considered 
statistically significant.
Conclusion
Twenty-six novel 5-oxo-hexahydroquinoline derivatives pos-
sessing variable activities against MDR cell line MES-SA/
Dx5 were designed and synthesized. The MDR reversal 
profile was evaluated using Rh123 as substrate and verapamil 
as a reference drug. The most potent compounds were sub-
jected to further evaluation by measurement of MES-SA-Dx5 
cells’ sensitivity to DXR by MTT assay. Compounds with 
2-nitrophenyl moiety such as 2c, 5c and 6c showed good 
activity profiles in both tests and proved to be the most inter-
esting molecules for further investigations. The effect of test 
compounds against HEK293 cell line was investigated at 5, 
10 and 25 µM, and no significant cytotoxicity was observed 
except for compound 2c. In order to understand the structural 
requirement of 5-oxo-hexahydroquinoline derivatives’ inter-
actions with P-gp, an MD simulation was performed, and the 
binding interactions of compound 5c in a homology-modeled 
human P-gp were investigated. The results indicated that 
stabilization of 5c occurs through different hydrogen bonds 
and also hydrophobic and arene–π interactions.
Abbreviations
3D, three-dimensional; ABC, ATP-binding cassette; DHPs, 
dihydropyridines; DMSO, dimethyl sulfoxide; DXR, 
doxorubicin; FBS, fetal bovine serum; IR, infrared; MD, 
molecular dynamics; MDR, multidrug resistance; NMR, 
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